 |
|
|
| |
Real-World Clinical Practice Outcomes in Hepatitis C-Infected Patients With Psychiatric and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 or 12 Weeks: A Pooled Analysis Across 9 Countries
|
| |
| |
EASL virtual
European Association for the Study of the Liver's Digital International Liver Congress, 27-29 August 2020
Reported by Jules Levin
Pietro Lampertico1,2, Robert Flisiak3, Nuno Marques4, Olivier Clerc5, Ioannis Goulis6, Mark Bondin7, Ariel Porcalla7, Zhenzhen Zhang7, Yves Horsmans8, Harald Hofer9, Ella Veitsman10, Georges Philippe Pageaux111Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Policlinico - Division of Gastroenterology and Hepatology - CRC "AM and A Migliavacca" Centre for Liver Disease, Milan, Italy; 2University of Milan, Milan, Italy; 3Department of Infectious Diseases and Hepatology, Medical University of Biaystok, Biaystok, Poland; 4Infectious Diseases Service, Hospital Garcia de Orta EPE, Almada, Portugal; 5Department of Internal Medicine and Infectious Diseases, Pourtales Hospital, Neuchâtel, Switzerland; 64th Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; 7AbbVie Inc, North Chicago, Illinois, United States; 8Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium; 9Department of Internal Medicine, Gastroenterology and Hepatology, Klinikum Wels-Grieskirchen, Wels, Austria; 10Liver Unit, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; 11Departement Hepato-gastro-enterologie, Centre Hospitalier Universitaire (CHU) de Montpellier, Montpellier Cedex 5, France
|
| |
|
|
|
|
|
